Pharmacokinetics of idarucizumab following administration of idarucizumab in
Pharmacokinetics of idarucizumab following administration of idarucizumab in middle-aged, elderly, RI: 60– 90 and RI: 30– 60 subjects AUC (nmol/h/litre) 80000 67900 60000 53100 40000 43900 37000 20000 22200 10700 8560 0 Middle-aged 2. 5 gr Elderly 1 gr Elderly 5 gr RI 60 -90 1 gr RI 60 -90 5 gr RI 30 -60 2 x 2, 5 gr AUC: area under the concentration–time curve from zero to infinity RI: renally impaired Based on: Glund S et al. , Clin Pharmacokinet 2016
Pharmacokinetics of idarucizumab following administration of idarucizumab in middle-aged, elderly, RI: 60– 90 and RI: 30– 60 subjects clearance (m. L/min) 50 47, 1 40 39, 3 40, 7 39, 6 32, 7 30 32, 8 25, 7 20 10 0 Middle-aged 2. 5 gr Elderly 1 gr Based on: Glund S et al. , Clin Pharmacokinet 2016 Elderly 5 gr RI 60 -90 1 gr RI 60 -90 5 gr RI 30 -60 2 x 2, 5 gr
Pharmacokinetics of idarucizumab following administration of idarucizumab in middle-aged, elderly, RI: 60– 90 and RI: 30– 60 subjects 1, 2 Initial half-life (hrs) 1, 16 1 0, 8 0, 91 0, 89 0, 8 0, 93 0, 9 0, 78 0, 6 0, 4 0, 2 0 Middle-aged Elderly 2. 5 gr gr 1 Based on: Glund S et al. , Clin Pharmacokinet 2016 Elderly 5 gr RI 60 -90 gr 1 RI 60 -90 5 gr RI 30 -60 2 x 2, 5 gr
- Slides: 3